2021
DOI: 10.1007/s12098-021-03767-9
|View full text |Cite
|
Sign up to set email alerts
|

Acute Appendicitis in Multisystem Inflammatory Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 4 publications
0
2
0
Order By: Relevance
“…Since he was diagnosed with MIS-C in time, the boy was not operated on. Normal leukocyte counts, low platelets, significantly elevated inflammatory markers, and echocardiographic changes may confirm MIS-C (59) . In a study by Al Maskari et al it is important to note that two of the six patients, suffering from MIS-C, presented to them with an acute abdomen.…”
Section: Discussionmentioning
confidence: 98%
See 1 more Smart Citation
“…Since he was diagnosed with MIS-C in time, the boy was not operated on. Normal leukocyte counts, low platelets, significantly elevated inflammatory markers, and echocardiographic changes may confirm MIS-C (59) . In a study by Al Maskari et al it is important to note that two of the six patients, suffering from MIS-C, presented to them with an acute abdomen.…”
Section: Discussionmentioning
confidence: 98%
“…appendicitis, segmental intestinal ischaemia) which need swift surgical treatment Al Lawati et al (2021) (55) Given the risk of severity and rapid deterioration of children with MIS-C, we recommend that surgeons, emergency physicians and paediatricians have a high index of MIS-C suspicion when managing children and adolescents with fever and acute abdomen during the current pandemic Borgi et al (2021) (56) A patient with MIS-C is considered to have a refractory disease when the child has persistent fever and/or significant end-organ involvement despite initial immunomodulatory treatment Lee et al (2021) (57) Early recognition by disease awareness and prompt management are key to saving the lives of children affected by MIS-C. The benefits of immunomodulatory therapy have been suggested in both MIS-C and severe paediatric COVID-19 patients, even though no guidelines support the use of one immunomodulatory therapy over another Lishman et al (2020) (58) Paediatricians that diagnose MIS-C should be vigilant and continue to carefully evaluate children for surgical complications, including appendicitis and perforation, particularly if abdominal pain is part of the presenting complaint (59) Normal leukocyte count, low platelets, significantly raised inflammatory markers, and echocardiographic changes can confirm MIS-C Al Maskari et al (2021) (60) Early diagnosis and referral to centres equipped with the required subspecialties are recommended. It should be noted that the severity of the disease is transient, usually resulting in high survival rates with proper supportive treatment.…”
Section: Discussionmentioning
confidence: 99%